Caligan Partners
Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, ALIM, ANIK, EXEL, LAB, and represent 87.44% of Caligan Partners's stock portfolio.
- Added to shares of these 3 stocks: LQDA (+$13M), AGIO (+$9.7M), YMAB (+$7.0M).
- Reduced shares in these 5 stocks: Intercept Pharmaceuticals In (-$22M), EOLS, LAB, VRCA, ADMA.
- Sold out of its positions in Intercept Pharmaceuticals In, VRCA.
- Caligan Partners was a net buyer of stock by $1.2M.
- Caligan Partners has $297M in assets under management (AUM), dropping by 36.17%.
- Central Index Key (CIK): 0001727492
Tip: Access up to 7 years of quarterly data
Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Caligan Partners
Caligan Partners holds 11 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corp Com New (LQDA) | 42.0 | $125M | +12% | 10M | 12.03 |
|
| Alimera Sciences Com New (ALIM) | 24.5 | $73M | 17M | 4.32 |
|
|
| Anika Therapeutics (ANIK) | 8.3 | $25M | 1.1M | 22.66 |
|
|
| Exelixis (EXEL) | 7.4 | $22M | 911k | 23.99 |
|
|
| D Fluidigm Corp Del (LAB) | 5.2 | $16M | -7% | 7.0M | 2.21 |
|
| Evolus (EOLS) | 4.7 | $14M | -21% | 1.3M | 10.53 |
|
| Agios Pharmaceuticals (AGIO) | 3.3 | $9.8M | +9042% | 442k | 22.27 |
|
| Y Mabs Therapeutics (YMAB) | 2.4 | $7.2M | +4395% | 1.0M | 6.82 |
|
| Verona Pharma Sponsored Ads (VRNA) | 1.2 | $3.6M | 183k | 19.88 |
|
|
| Adma Biologics (ADMA) | 0.7 | $2.1M | -20% | 473k | 4.52 |
|
| Recro Pharma (SCTL) | 0.2 | $592k | 1.7M | 0.35 |
|
Past Filings by Caligan Partners
SEC 13F filings are viewable for Caligan Partners going back to 2022
- Caligan Partners 2023 Q4 filed Feb. 14, 2024
- Caligan Partners 2023 Q3 filed Nov. 14, 2023
- Caligan Partners 2023 Q2 filed Aug. 14, 2023
- Caligan Partners 2023 Q1 filed May 15, 2023
- Caligan Partners 2022 Q4 restated filed May 15, 2023
- Caligan Partners 2022 Q4 filed Feb. 15, 2023